Keystone Symposia

Fairmont Chateau Whistler Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2018


Here are the related meetings in 2020:
Tuberculosis: Immunity and Immune Evasion (A2)
MEETING CANCELLED: HIV Pathogenesis and Cure (X6)

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

HIV and Co-Infections: Pathogenesis, Inflammation and Persistence (X8)


Organizer(s) Irini Sereti, Nicolas Chomont and Michaela Müller-Trutwin
April 15—19, 2018
Fairmont Chateau Whistler • Whistler, BC Canada
Discounted Abstract Deadline: Dec 13, 2017
Abstract Deadline: Jan 11, 2018
Scholarship Deadline: Dec 13, 2017
Discounted Registration Deadline: Feb 15, 2018

Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation


Summary of Meeting:
Better understanding of HIV pathogenesis is the cornerstone for advances in HIV prevention and vaccine design, long-term therapies and strategies for remission or eradication. Despite remarkable progress in the care of HIV-infected individuals and successful conversion of HIV into a chronic disease, gaps in knowledge regarding the mechanisms of evasion of immune responses, establishment of latency and persistence, pathways involved in chronic inflammation and the potential role of co-infections persist and hamper the design of targeted interventions. This meeting aims to: 1) Deepen understanding the mechanisms of establishment and maintenance of HIV reservoirs including viral evolution on ART, epigenetic regulations and metabolic states; 2) Provide updates on innovative strategies for HIV remission and control; 3) Determine the role of TB and other co-infections in inflammation and establishment of HIV viral reservoirs; and 4) Explore the pathways that induce chronic inflammation and the molecular interplays between inflammation and viral reservoirs in chronic HIV infection. The conference is novel because it is being paired with Keystone Symposia’s conference on “Tuberculosis: Translating Scientific Findings for Clinical and Public Health Impact.” Of the estimated 34 million people living with HIV in the world today, more than a third are also infected with Mycobacterium tuberculosis. Important questions related to HIV pathogenesis including pathways of inflammation and establishment of reservoirs may be greatly influenced by TB and other co-infections. Inflammation and viral persistence are likely fueled by each other, which provides a rationale for addressing these two topics in the same conference. In addition, the meeting’s joint pairing with one dedicated to TB should facilitate interdisciplinary interactions and highlight the importance of TB in HIV pathogenesis and vice versa.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


The meeting will begin on Sunday, April 15 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, April 19 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, April 20 in order to fully experience the meeting.

SUNDAY, APRIL 15

16:00—20:00
Arrival and Registration

Macdonald Foyer
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Macdonald Foyer

MONDAY, APRIL 16

07:00—08:00
Breakfast

Frontenac/Empress
08:00—09:30
Welcome and Keynote Session (Joint)

Macdonald Ballroom
* Irini Sereti, NIAID, National Institutes of Health, USA

* Graeme Meintjes, University of Cape Town, South Africa

Bruce D. Walker, Ragon Institute of MGH, MIT and Harvard, USA
New Insights into HIV Pathogenesis: Implications for Immunotherapeutic Strategies

Gavin J. Churchyard, Aurum Institute NPC, South Africa
Translating TB Science to Impact the Epidemic

Coffee Break

09:50—12:00
Off to a Strong Start: Lessons from Acute HIV Infection

Macdonald DEF
* Nicolas Chomont, Université de Montréal, Canada

* Ann Duerr, Fred Hutchinson Cancer Research Center, USA

Thumbi Ndung'u, University of KwaZulu-Natal, South Africa
Evidence of Transmission-Virulence Evolutionary Trade-Offs in the Spread of HIV-1 Subtypes

Julie Mitchell, Vaccine and Gene Therapy Institute, OHSU, USA
T Cell Responses in Acutely Infected Young Men in Thailand

John Frater, University of Oxford, UK
Predictors of Outcome in Primary HIV Infection

Elina El-Badry, Emory University, USA
Short Talk: Zambian Women Exhibit an Exacerbated Inflammatory Response to Early HIV Infection Compared to Men

Heeva Baharlou, Westmead Institute for Medical Research, Australia
Short Talk: HIV and the Colorectal Mucosa – Investigating the Early Interactions of HIV with Mucosal Target Cells in situ

09:50—12:15
Prospects for Epidemic Control and the Scientific Insights Required

Macdonald ABC
* Eric J. Rubin, Harvard T.H. Chan School of Public Health, USA

* Henry Charles Mwandumba, Liverpool School of Tropical Medicine, UK

Richard E. Chaisson, Johns Hopkins University, USA
Treatment of Latent TB for Epidemic Control

Mark Hatherill, University of Cape Town, South Africa
Translating Transcriptomic Insights into Clinical Tools

Carole D. Mitnick, Harvard Medical School, USA
(Re)Moving the Needle in Treatment for Rifampin-Resistant TB: The endTB Trial

Michael Gordon Whitfield, Stellenbosch University, South Africa
Short Talk: The Potential of Rifabutin for the Treatment of Rifampicin-Resistant Tuberculosis

Francesca Tomasi, Harvard T. H. Chan School of Public Health, USA
Short Talk: Small Molecule Inhibitors of Amino Acid Metabolism in Mycobacterium tuberculosis: A Model with Acivicin

Meera Gurumurthy, International Union Against Tuberculosis and Lung Disease, Singapore
Short Talk: Randomised Controlled trial of Pascolizumab (Anti-IL-4 Monoclonal Antibody) as an Adjunct to Standard TB Treatment

12:00—17:00
On Own for Lunch

12:00—13:00
Poster Setup

Frontenac/Empress
13:00—22:00
Poster Viewing

Frontenac/Empress
14:30—16:30
Workshop 1: Role of Metabolism and Inflammation in SIV/HIV Pathogenesis and Reservoirs

Macdonald DEF
* Asier Sáez-Cirión, Institut Pasteur, France

* Michael A. Eller, US Military HIV Research Program, USA

Cristian Apetrei, University of Pittsburgh, USA
High Fat Diet Exacerbates SIV Pathogenesis in SIVsab Infection Models

Mohamed Abdel-Mohsen, Wistar Institute, USA
Plasma and Immunoglobulin G Galactosylation Associate with HIV Persistence During Antiretroviral Therapy

Livia Ramos Goes, Instituto Nacional de Cancer, Brazil
MAdCAM Costimulation in Presence of Retinoic Acid Promotes Viral Replication in Recently Activated Naïve CD4+ T Cells

Virginie W. Gautier, University College Dublin, Ireland
Targeting HIV Latency with Metabolic Cues

Sergei Nekhai, Howard University, USA
Upregulated Iron Metabolism Induces Intrinsic HIV-1 Restriction in Sickle Cell Disease

Sandra Milena Gonzalez Diaz, Universidad de Antioquia, Colombia
Active and Inactive Forms of Vitamin D Reduce the HIV-1 Infection of CD4+ T Cells in Vitro and Modulate their Activation Level

Emily Bowman, Ohio State University, USA
Altered Macrophage Phenotype in HIV Infection May Contribute to Vascular Inflammation

Robert Blomgran, Linköping University, Sweden
HIV Interferes with The DC-T Cell Axis of Macrophage Activation by Shifting Mycobacterium tuberculosis-Specific CD4 T Cells into a Dysfunctional Tolerized Phenotype

14:30—16:30
Workshop 1: TB Vaccines

Macdonald ABC
* Cesar A. Boggiano, NIAID, National Institutes of Health, USA

* Willem A. Hanekom, Bill & Melinda Gates Foundation, USA
State of the TB Vaccine Field

Karen Lacourciere, NIAID, National Institutes of Health, USA
Funding Opportunities in TB Vaccine Research

Lakshmi Ramachandra, NIAID, National Institutes of Health, USA
Funding Opportunities in TB Vaccine Research

Tracey Day, Infectious Disease Research Institute, USA
Clinical Development of ID93+GLA-SE as a Prophylactic or Therapeutic Vaccine for Tuberculosis

Stephen C. De Rosa, University of Washington, Fred Hutchinson Cancer Research Center, USA
BCG Revaccination Significantly Boosts Circulating, Polyfunctional, Mtb-Specific CD4 T Cell Effector Responses in Young Adults with Latent TB Living in South India

Karin Dijkman, Biomedical Primate Research Centre, Netherlands
Local IL17A after Mucosal BCG Vaccination Associates with Protection from Infection and Disease in a Novel, Repeated Ultra-Low Dose TB Challenge Model in Rhesus Macaques

Ved Prakash Dwivedi, International Center for Genetic Engineering and Biotechnology, India
Mimicking Mycobacterium tuberculosis for the Immunization in the Lung thereby Generating Effective Vaccine in the Local Milieu

Sasha E. Larsen, Universty of Washington, USA
Therapeutic Immunizations Induce Control of Bacterial Burden and Increase Survival in a Preclinical Mouse Model of Mycobacterium tuberculosis

Elisa Nemes, University of Cape Town, South Africa
Prevention of Infection with Mycobacterium tuberculosis by H4:IC31® Vaccination or BCG Revaccination in Adolescents  

16:30—17:00
Coffee Available

Macdonald Foyer
17:00—19:00
New and Old Players in Mucosal Immunity and their Role in HIV/SIV Infection

Macdonald DEF
* Barbara L. Shacklett, University of California, Davis, USA

* Karl Salzwedel, NIAID, National Institutes of Health, USA

Johan K. Sandberg, Karolinska Institute, Sweden
Role of MAIT Cells in Immune Defense and HIV Immunopathogenesis

Petronela Ancuta, Centre de Recherche de l'Universite de Montreal, Canada
HIV Persistence in Th17 Cells: Finding New Ways to Cure

Jason M. Brenchley, NIAID, National Institutes of Health, USA
Mechanisms Underlying Loss of ILCs in Progressive SIV Infection

Dominic Paquin Proulx, US Military HIV Research Program, USA
Short Talk: Permanent Loss of Regulatory Colonic CD4+ iNKT Cells in Early Acute HIV-1 Infection

17:00—19:00
Mycobacterium Tuberculosis and Host Evasion

Macdonald ABC
* Sarah M. Fortune, Harvard TH Chan School of Public Health, USA

* Joel D. Ernst, University of California, San Francisco, USA

JoAnne L. Flynn, University of Pittsburgh School of Medicine, USA
Granuloma Dynamics in Tuberculosis

Robert A. Seder, NIAID, National Institutes of Health, USA
A Novel Approach to BCG Vaccination in the NHP Model

Jennifer Philips, Washington University School of Medicine, USA
Hijacking the Host – Molecular Interactions between Host and Pathogen

Samuel M. Behar, University of Massachusetts Medical School, USA
Short Talk: Decoy Antigens Elicit Immunodominant T Cell Responses that Fail to Recognize Infected Macrophages

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Frontenac/Empress
19:30—22:00
Poster Session 1

Frontenac/Empress

TUESDAY, APRIL 17

07:00—08:00
Breakfast

Frontenac/Empress
07:30—08:00
Poster Setup

Frontenac/Empress
08:00—17:00
Poster Viewing

Frontenac/Empress
08:00—11:15
Innate Responses in HIV and SIV Infection: The Good, the Bad and the Splendid

Macdonald DEF
* R. Keith Reeves, Harvard Medical School, USA

* Anthony L. Cunningham, Westmead Institute for Medical Research, Australia

Marcus Altfeld, Heinrich-Pette-Institute, Germany
Innate Immune Responses in HIV-1: Mediators of Viral Control and Immune Activation

Michaela Müller-Trutwin, Institut Pasteur, France
Innate Immune Responses in Non-Pathogenic SIV Infection

Coffee Break

Teunis B.H. Geijtenbeek, University of Amsterdam, Netherlands
Innate Responses by Dendritic Cells in HIV Infection – A Role in Pathogenesis

Tram N.Q. Pham, Institut de Recherches Cliniques de Montreal, Canada
Short Talk: Flt3L Treatment Reduces HIV Infection and Replication in Humanized Mice via a Plasmacytoid Dendritic Cell-Dependent Process

Henrik N. Kloverpris, University of KwaZulu-Natal, South Africa
Short Talk: HIV-Infected Children Have Life-Long Depletion of all Circulating Innate Lymphoid Cells (ILCs) but Respond to Infection through Tissue-Resident ILCs

Daniel Claiborne, Ragon Institute of MGH, MIT, and Harvard, USA
Short Talk: Integral Role of Monocytes in Immune Activation during HIV-1 Infection

Ivona Pandrea, University of Pittsburgh, USA
Short Talk: Neutrophil Extracellular Trap (NET) Production in SIV-Infected Nonhuman Primates

08:00—11:15
Drug Tolerance and Resistance

Macdonald ABC
* Sabine Ehrt, Weill Cornell Medical College, USA

* Christopher M. Sassetti, University of Massachusetts Medical School, USA

Eric J. Rubin, Harvard T.H. Chan School of Public Health, USA
I Guess You're Just What I Needed – What Does it Mean to Be Essential?

Bree B. Aldridge, Tufts University, USA
Efficient Measurement and Analysis of High-Order Drug Interactions

Coffee Break

Luiz Pedro Carvalho, Francis Crick Institute, UK
How to Make "Resistance-Proof" Antibiotics?

Mark Ragheb, University of Washington, USA
Short Talk: Mfd Promotes Rapid Evolution of Antibiotic Resistance

Sarah M. Fortune, Harvard TH Chan School of Public Health, USA
Multi-Drug-Tolerant Mutants Identified through a Population GWAS

Bryan J. Berube, Infectious Disease Research Institute, USA
Short Talk: Dual Targeting of the M. tuberculosis Electron-Transport Chain Enhances Bacterial Killing and Limits Spontaneous Mutant Formation

11:15—12:00
Lunch

Frontenac/Empress
12:00—14:30
Poster Session 2

Frontenac/Empress
14:30—16:30
Workshop 2: HIV, TB and Other Co-Infections (Joint)

Macdonald Ballroom
* Donald L. Sodora, Center for Infectious Disease Research, USA

* Shelby O'Connor, University of Wisconson-Madison, USA

Allison Nicole Bucsan, Tulane National Primate Research Center, USA
Mtb/SIV Co-Infection Induces Differential T Cell Responses in Rhesus Macaques

Anna Kathleen Coussens, Walter and Eliza Hall Institute, Australia
GBPs in TB-HIV, A Double-Edge Sword in Prevention and Progression

Rabiah Fardoos, Africa Health Research Institute, South Africa
Profiling of HIV and CMV-Specific CD8+ T-Cells Isolated from HIV-Infected Human Lymphoid Tissue Display a Distinct Phenotype Compartmentalization

Collin Richard Diedrich, University of Pittsburgh, USA
SIVmac251 and Neutralizing CD4 T Cell Antibodies Induce Reactivation of Latent Tuberculosis Infection by Distinct Mechanisms

Amy Kathryn Dickey, Massachusetts General Hospital, Ragon Institute, USA
Slam Family Receptors May Act as Inhibitory Receptors in the Airways of HIV-Infected Individuals

Annapurna Vyakarnam, King's College London, UK
HIV Alters the Mtb-Specific Th17 Response in Latent TB

Joshua T. Mattila, University of Pittsburgh, USA
Type 3 Interferons Are Expressed in Tuberculous Granulomas and May Influence Signaling in Epithelioid Macrophages

Fatoumatta Darboe, Medical Research Council, The Gambia Unit, Gambia
A Transcriptomic Risk Signature Predicts Subclinical TB in HIV-Infected Persons on Highly Active Antiretroviral Therapy

16:30—17:00
Coffee Available

Macdonald Foyer
17:00—19:00
New Insights in Pathogenesis: Tissue Is the Issue

Macdonald DEF
* Thomas J. Hope, Northwestern University, USA

* Marianne E. Jansson, Lund University, Sweden

Michael R. Betts, University of Pennsylvania, USA
Lymphocyte Trafficking in HIV Infection

Eli Andrew Boritz, NIAID, National Institutes of Health, USA
HIV Reservoirs in Lymph Nodes

Shelli Farhadian, Yale School of Medicine, USA
Short Talk: Single-Cell RNA Sequencing to Characterize CSF during Virologically Suppressed HIV

Abigail E. Schiff, Harvard University, USA
Short Talk: Investigation of Alveolar Macrophage Phagocytosis of HIV-Infected T Cells as a Mechanism of HIV-1 Entry into Macrophages

Johanne Hovgaard Egedal, Aarhus University, Denmark
Short Talk: Hyaluronic Acid on Mucosal Fibroblasts Limits their Ability to Enhance HIV Infection of CD4+ T Cells

17:00—19:00
Immune-Pathogen Interaction: Containment or Progression?

Macdonald ABC
* Tom H. M. Ottenhoff, Leiden University Medical Center, Netherlands

* Clifton E. Barry III, NIAID, National Institutes of Health, USA

Bryan D. Bryson, Massachusetts Institute of Technology, USA
Enhancing Control of Mycobacterium tuberculosis Infection with Single-cell Resolution

Christina L. Stallings, Washington University School of Medicine, USA
Innate Immune Determinants of TB Progression

David M. Lewinsohn, Oregon Health & Science University, USA
MAIT Cell Responses to the TB Metabolome and Implications for Vaccine Development

Daisy Xiaoxi Ji, University of California, Berkeley, USA
Short Talk: A Mechanism for Interferon-Driven Susceptibility to M. tuberculosis

19:00
On Own for Dinner


WEDNESDAY, APRIL 18

07:00—08:00
Breakfast

Frontenac/Empress
08:00—11:15
HIV and TB: Double Trouble (Joint)

Macdonald Ballroom
* Michaela Müller-Trutwin, Institut Pasteur, France

* Richard E. Chaisson, Johns Hopkins University, USA

Graeme Meintjes, University of Cape Town, South Africa
High Early Mortality in Patients Diagnosed with HIV-Associated TB in Hospital

Gregory Bisson, University of Pennsylvania, USA
To Have and Have Not: Immune Restoration and Lung Injury in HIV/TB

Coffee Break

Irini Sereti, NIAID, National Institutes of Health, USA
Role of Co-Infections in HIV Inflammation and Persistence

Henry Charles Mwandumba, Liverpool School of Tropical Medicine, UK
HIV and TB Co-Infection: A View from the Lungs

Daniel Kalman, Emory University, USA
Short Talk: The Imatinib-TB Clinical Trial

Mark Andrew Rodgers, University of Pittsburgh, USA
Short Talk: Pre-Existing SIV Infection Increases Susceptibility of Mauritian Cynomolgus Macaques to M. tuberculosis

11:15—17:00
On Own for Lunch

11:15—13:00
Poster Setup

Frontenac/Empress
11:15—12:15
Grantsmanship Workshop presented by NIAID (Joint)
NIAID Workshop Objectives: Come find out what happens to your applications after you submit it to the NIH. NIAID staff will provide attendees with an overview of NIH peer-review, and provide some grantsmanship tips. NIAID Program Officers and Scientific Review Officers will explain their role in shepherding your grants/proposals through the process. Staff will also provide attendees with resources that will alert them to NIAID funding opportunities and discuss specific opportunities targeted to research in mycobacterial diseases. Finally, time permitting staff will discuss various career opportunities within the NIH.

Macdonald Ballroom
* Alison Kraigsley, NIAID, National Institutes of Health, USA

* Karen Lacourciere, NIAID, National Institutes of Health, USA

* Susana Mendez, NIAID, National Institutes of Health, USA

* Vasundhara Varthakavi, NIDA, National Institutes of Health, USA

* Roberta Binder, NIAID, National Institutes of Health, USA

* Chelsea Boyd, NIAID, National Institutes of Health, USA

13:00—22:00
Poster Viewing

Frontenac/Empress
14:30—16:30
Workshop 3: Persistence, Latency and Eradication

Macdonald DEF
* Remi Fromentin, Le Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Canada

* Alberto Bosque, George Washington University, USA

Christina Gavegnano, Emory University, USA
Baricitinib Reverses HIV-Associated Neurocognitive Disorders and Reservoir Seeding in a SCID Mouse Model

Patrick Budylowski, University or Toronto, Canada
Discovering Novel Surface Biomarkers on Latent HIV-Infected CD4 T Cells using VLR Antibodies

Namita Satija, Icahn School of Medicine at Mount Sinai, USA
A Genetically Encoded Switch to Monitor HIV Latent Cells in Humanized Mice

Mykola Pinkevych, University of New South Wales, Australia
Using a Barcoded Virus to Assess Replication Competent SIV Reservoir Size

Sara Cristinelli, University of Lausanne, Switzerland
Single-Cell RNA-Seq Reveals Transcriptional Heterogeneity in Latent and Reactivated HIV-Infected Cells

Gregory Q. Del Prete, Frederick National Laboratory for Cancer Research, USA
CD4 Depletion in SIV-Infected Macaques on Early ART Has No Impact on Viral Rebound

Maria-Louise Røn Kobberø, Aarhus University Hospital, Denmark
Immunological Effects of Toll-Like Receptor 9 Agonist Treatment in Lymph Nodes of HIV-1+ Adults on ART

Mirko Paiardini, Emory University, YNPRC, USA
IL-10 Signaling Contributes to Viral Persistence in ART-Treated, SIV-Infected Rhesus Macaques

14:30—16:30
Workshop 3: MTB Growth and Death

Macdonald ABC
* Eric J. Rubin, Harvard T.H. Chan School of Public Health, USA

* Bavesh Davandra Kana, University of the Witwatersrand, South Africa

Piyali S. Basu, University of Surrey, UK
Nitrogen Metabolism in Mycobacterium tuberculosis: A Systems-Based Approach

Viktoria Betin, Harvard University, USA
Determining How Mycobacterium tuberculosis Transcriptional Regulators Influence Intracellular Replication

Allison F. Carey, Harvard School of Public Health, USA
TnSeq of M. tuberculosis Clinical Isolates Reveals Strain-Specific Antibiotic Liabilities

Marcus A. Horwitz, University of California, Los Angeles, USA
Identification by Parabolic Response Surface Methodology of a Universal TB Drug Treatment Regimen that, Compared with the Standard Regimen, Reduces the Time to Achieve Relapse-Free Cure in Mice from 20 Weeks to Only 4 Weeks

Johana Hernandez, University of Surrey, UK
Investigating Candidate Genes Affecting Persistence (drug tolerance) of Mycobacterium tuberculosis Obtained by Tn-Seq Analysis

Christopher R. Covey, University of Colorado, USA
Myocbactin Inhibits Clofazimine Killing of Mycobacteria

John T. Williams, Michigan State University, USA
Novel Inhibitors that Kill Mycobacterium tuberculosis by Targeting MmpL3

Hua Wang, Francis Crick Institute, UK
The Discovery of a Multi-Functional acyl-CoA Lyase Shared by Three Metabolic Pathways in Mycobacterium tuberculosis

16:30—17:00
Coffee Available

Macdonald Foyer
17:00—19:00
HIV and Co-infections: Dangerous Liaison

Macdonald DEF
* Peter W. Hunt, University of California, San Francisco, USA

* Neeltje A. Kootstra, Amsterdam UMC, Netherlands

Andrea Lynn Cox, Johns Hopkins University, USA
HIV- and HCV-Induced Inflammation

Victor Appay, INSERM U1135 - CIMI, France
Immune Aging and Co-Infections in HIV

Elena Martinelli, Population Council, USA
Role of Herpes Simplex in HIV/SIV Infection

Stephen R. Morris, Louis Stokes Cleveland VA Medical Center, USA
Short Talk: IL-15 Drives the Generation and Survival of Senescent CD8 T Cells in HIV/CMV Co-Infection

17:00—19:00
The Cellular, Anatomical and Pathological Niches of TB Infection and Disease

Macdonald ABC
* Graeme Meintjes, University of Cape Town, South Africa

* David M. Lewinsohn, Oregon Health & Science University, USA

Clifton E. Barry III, NIAID, National Institutes of Health, USA
Imaging TB

Sabine Ehrt, Weill Cornell Medical College, USA
Resist, Persist and Divide

Veronique Anne Dartois, Hackensack Meridian Health, USA
Lesion-Centric Pharmacology to Design New Drug Regimens for Tuberculosis

Valerie A.C.M. Koeken, Radboud University Medical Center, Netherlands
Short Talk: Survival of Tuberculous Meningitis Is Linked to Cerebrospinal Fluid Vascular Endothelial Growth Factor (VEGF); a Systems Approach

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Frontenac/Empress
19:30—22:00
Poster Session 3

Frontenac/Empress

THURSDAY, APRIL 19

07:00—08:00
Breakfast

Frontenac/Empress
08:00—11:15
HIV Persistence and Latency: The Enemy Within

Macdonald DEF
* Mark Brockman, Simon Fraser University, Canada

* Camille M. Lange, National Cancer Institute, USA

B. Matija Peterlin, University of California, San Francisco, USA
HIV Latency and Reactivation

Nicolas Chomont, Université de Montréal, Canada
HIV Persistence and Aging

Coffee Break

Ya-Chi Ho, Yale School of Medicine, USA
HIV-1 Viral and Proviral Landscape

James I. Mullins, University of Washington, USA
HIV Integration Sites and Selection for Infected Cell Survival in Persisting Reservoirs

Kelsie Brooks, Emory University, USA
Short Talk: Proviral Sequences of the Reservoir Demonstrate Archiving of Transmitted/Founder Virus-Like Variants

Timothée Bruel, Institut Pasteur, France
Short Talk: Characterization of Circulating CD32a+ CD4 T Cells and Identification of Potent ADCC-Mediating CD32 Antibodies

08:00—11:15
Bacterial Adaptation

Macdonald ABC
* Luiz Pedro Carvalho, Francis Crick Institute, UK

* Sabine Ehrt, Weill Cornell Medical College, USA

David Alland, Rutgers University, New Jersey Medical School, USA
Genetic Diversity of Mycobacterium tuberculosis as a Driver of Drug Resistance and Relapse in Human TB

Stefan Niemann, Research Center Borstel, Germany
Recent Evolution and Transmission of MDR M. tuberculosis Strains

Coffee Break

Hesper Rego, Yale Medical School, USA
Exploring the Molecular Basis of Pathogen Heterogeneity

Sarah Bwabye Namugenyi, University of Minnesota, USA
Short Talk: Identification of Mycobacterium tuberculosis Immune Evasion Mechanisms using Tn-seq

Babak Javid, Tsinghua University School of Medicine, China
Targeting Mycobacterial Adaptive Mistranslation in Vitro and in Vivo

Eduardo Pinheiro Amaral, NIAID, National Institutes of Health, USA
Short Talk: Ferroptosis, an Iron-Dependent Cell Death Modality, Is a Major Mechanism of Regulated Necrosis in Mycobacterium tuberculosis Infection

11:15—17:00
On Own for Lunch

14:30—16:30
Workshop 4: The Immune Response to TB

Macdonald ABC
* Bryan D. Bryson, Massachusetts Institute of Technology, USA

* Thomas J. Scriba, University of Cape Town, South Africa

Jayne S. Sutherland, Medical Research Council, Gambia
Analysis of Early Protective Immunity to Mycobacterium tuberculosis Infection

Amanda Lee Ardain, Africa Health Research Institute, South Africa
Innate Lymphoid Cells Mediate Early Protective Immunity against Mycobacterium tuberculosis

Eusondia Arnett, Texas Biomedical Research Institute, USA
Use of a Tissue Culture Model to Characterize M. tuberculosis HIV Co-Infected Human Granuloma Development

Julie Boucau, Ragon Institute of MGH, MIT and Harvard, USA
Mycobacterium tuberculosis Antigens Are Differentially Degraded into Epitopes by Human Monocyte-Derived Dendritic Cells and Macrophages

Natasha M. Bourgeois, University of Washington School of Medicine, USA
Host-Directed Macrophage Therapy with Kinase Inhibitors Limit Mycobacterium tuberculosis Replication and Modulate Cytokine Signaling

Alissa C. Rothchild, Seattle Children's Research Institute, USA
In vivo Response of Alveolar Macrophages to Mycobacterium tuberculosis

Munyaradzi Nyasha Musvosvi, University of Cape Town, South Africa
T Cell Biomarkers for Diagnosis of Tuberculosis: Candidate Evaluation by a Simple Whole Blood Assay for Clinical Translation

Michael D. Stutz, , Australia
Harnessing the Therapeutic Potential of Endogenous TNF for the Treatment of Tuberculosis

16:30—17:00
Coffee Available

Macdonald Foyer
17:00—18:45
Strategies for HIV Remission and Cure

Macdonald DEF
* Jana Blazkova, NIAID, National Institutes of Health, USA

* Michael M. Lederman, Case Western Reserve University, USA

Asier Sáez-Cirión, Institut Pasteur, France
Cell Metabolism and HIV Control

Romas Geleziunas, Gilead Sciences, Inc., USA
TLR7 Agonists for HIV

Paula M. Cannon, University of Southern California, Keck School of Medicine, USA
Genetic Strategies for HIV Cure

17:00—18:45
New Frontiers in TB Diagnostics and Treatment

Macdonald ABC
* David Alland, Rutgers University, New Jersey Medical School, USA

Bavesh Davandra Kana, University of the Witwatersrand, South Africa
Differentially Culturable Tubercle Bacteria: Implications for Diagnosis and Measuring Treatment Efficacy

Nader Fotouhi, TB Alliance, USA
TB Alliance Drugs in Development

Jane Hill, Dartmouth College, USA
Exhaled Breath: A Diagnostic Fluid that also Generates Insight into Pathogenesis

18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

Macdonald DEF
18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

Macdonald ABC
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Frontenac/Empress
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Frontenac

FRIDAY, APRIL 20

 
Departure


*Session Chair †Invited, not yet responded.


We gratefully acknowledge support for this conference from:


Directors' Fund

These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.

Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:

Bill & Melinda Gates Foundation

We gratefully acknowledge additional support for this conference from:

Pathogens and Immunity

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Gilead Sciences, Inc.

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations

If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Corporate Relations, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org,
Phone:+1 970-262-1179